While GIP antibodies such as GIPg013 have been developed primarily as a research tool to assess the biological roles and actions of native GIP (Ravn et al. 2013, Table 1), others have been investigated as potential pharmacological interventions in obesity. This evidence concerns the gene GIP and obesity disorder.